Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0717 • ACR Convergence 2023
Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica
Despoina Michailidou¹, Linda Johansson², Jorge Armando Gonzalez-Chapa¹, Ting Wang¹, Junmei Chen³, José A. López³, Solbritt Rantapää-Dahlqvist⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Umea University, Umea, Sweden, ³Bloodworks Research Institute, Seattle, WA, ⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Platelets have been suggested to be involved in polymyalgia rheumatica (PMR) pathogenesis with elevated platelet activation observed in early stages of the disease. Upon…
Abstract Number: 1890 • ACR Convergence 2023
Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features
Emily Martin¹, Christopher McMaster¹, Saskia Rowson¹, Victor Yang¹, Aurora Poon¹, Bonnia Liu¹, Jessica Leung², Andrew Scott¹, David Liew¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Preston, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: PET/CT is a highly sensitive and specific test for diagnosing PMR.(1) This study investigated the utility of 18F-FDG whole body PET/CT in patients presenting…
Abstract Number: 0718 • ACR Convergence 2023
Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
Jeffrey Curtis¹, Lita Araujo², Stefano Fiore², Sebastian Sattui³, John Stone⁴, Kerri Ford² and Fenglong Xie⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Cambridge, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁵Illumination Health, Hoover, AL
Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…
Abstract Number: 2392 • ACR Convergence 2023
Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
andre ramon¹, helene Greigert², corentin Richard³, claudie cladière⁴, coraline genet⁵, marion ciudad⁶, georges tarris⁷, laurent martin⁸, louis arnould⁹, catherine creuzot-garcher¹⁰, paul ornetti¹¹, Sylvain Audia¹², romain boidot³, jean-Francis Maillefert¹¹, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁷Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, ⁸Department of Pathology, Dijon University Hospital, Dijon, France, ⁹Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, ¹⁰Department of Ophthalmology, Dijon University Hospital, Dijon, France, ¹¹Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
Abstract Number: 0719 • ACR Convergence 2023
Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
Lindsay Lally¹, Aliza Bloostein¹, Deanna Jannat-Khan¹ and Robert Spiera², ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…
Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
andre ramon¹, helene Greigert², adrien guilloteau³, claudie cladière⁴, marion ciudad⁵, Sylvain Audia⁶, paul ornetti⁷, jean-Francis Maillefert⁷, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, ⁷Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
Abstract Number: 0720 • ACR Convergence 2023
Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Over the past decade our understanding of the prevalence, and indeed impact of cognitive impairment in rheumatic diseases has increased. Intact cognitive function is…
Abstract Number: 2395 • ACR Convergence 2023
Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Kresten Keller¹, Chetan Mukhtyar², Andreas Wiggers Nielsen³, Andrea Hemmig⁴, Sarah Mackie⁵, Sebastian Sattui⁶, Ellen Margrethe Hauge³, Anisha Dua⁷, Toby Helliwell⁸, Lorna Neil⁹, Daniel Blockmans¹⁰, Valerie Devauchelle¹¹, eric Hayes³, Annett Jansen Venneboer¹², Sara Monti¹³, Cristina Ponte¹⁴, Eugenio De Miguel¹⁵, Mark Matza¹⁶, Kenneth Warrington¹⁷, Kevin Byram¹⁸, Kinanah Yaseen¹⁹, Christine Peoples²⁰, Mike Putman²¹, Lindsay Lally²², Michael Finikiotis²⁰, Simone Appenzeller²³, Ugo Carmori²³, CARLOS ENRIQUE TORO GUTIERREZ²⁴, Elisabeth Backhouse²⁵, Maria Camila Guerrero²⁶, Victor Pimentel-Quiroz²⁷, Helen Keen²⁵, Claire Owen²⁸, Thomas Daikeler²⁹, Annette De Thurah³, Wolfgang Schmidt³⁰, Elisabeth Brouwer¹² and Christian Dejaco³¹, ¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴University of Basel, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Northwestern University, Chicago, IL, ⁸Keele University, Keele, United Kingdom, ⁹Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Perth, United Kingdom, ¹⁰Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹¹UBO, Brest, France, ¹²University Medical Center Groningen, Groningen, Netherlands, ¹³Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ¹⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶Massachusetts General Hospital, Newton, MA, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸Vanderbilt University Medical Center, Nashville, TN, ¹⁹Cleveland Clinic, Cleveland, OH, ²⁰University of Pittsburgh Medical Center, Pittsburgh, PA, ²¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²²Hospital for Special Surgery, New York, NY, ²³UNICAMP, Campinas, Brazil, ²⁴Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ²⁵University of Western Australia, Daglish, Australia, ²⁶General practice, Cali, Colombia, ²⁷Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ²⁸Austin Health, Malvern East, Australia, ²⁹Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ³⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Existing EULAR/ACR guidelines on polymyalgia rheumatica (PMR) are focused on the management by rheumatologists. However, there is no consensus regarding early referral and evaluation…
Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 2404 • ACR Convergence 2023
Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk
Eugenio De Miguel¹, Rositsa Karalilova², PIERLUIGI MACCHIONI³, Cristina Ponte⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Sara Monti⁷, Irene Monjo¹, Zguro Batalov², Giulia Klinowski⁸, Paolo Falsetti⁹, David Kane¹⁰, Corrado Campochiaro¹¹ and Alojzija Hocevar¹², ¹Hospital Universitario La Paz, Madrid, Spain, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁸IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁹San Raffaele Scientific Institute, Siena, Italy, ¹⁰Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ¹²Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
Abstract Number: 0747 • ACR Convergence 2023
Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
Abstract Number: 2516 • ACR Convergence 2023
The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Katrina Nguyen¹, Jennifer Du¹, Jiaxiao shi² and Antony Lin¹, ¹Kaiser SCAL, Fontana, CA, ²SCPMG, Pasadena, CA
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
Abstract Number: 1036 • ACR Convergence 2023
The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study
Alojzija Hocevar¹, PIERLUIGI MACCHIONI², Irene Monjo³, Rositsa Karalilova⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Cristina Ponte⁷, Sara Monti⁸, Giulia Klinowski⁹, Zguro Batalov⁴, Paolo Falsetti¹⁰, Corrado Campochiaro¹¹ and Eugenio De Miguel³, ¹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁸Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁹IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ¹⁰San Raffaele Scientific Institute, Siena, Italy, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: Musculoskeletal ultrasound (US) is a validated method for the objective assessment of the pathological changes occurring in PMR. It assists the diagnosis of the…
Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Sebastian Sattui¹, Zihan Wan², Fenglong Xie², Cassie Clinton², Robyn Domsic¹ and Jeffrey Curtis³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…
Abstract Number: 1547 • ACR Convergence 2022
Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
Jeffrey Curtis¹, Kerri Ford², Stefano Fiore³, Danielle Isaman⁴, Lita Araujo⁵, Natalia Petruski-Ivleva⁶ and Fenglong Xie⁷, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Destin, FL, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Chapel Hill, NC, ⁵Sanofi, Cambridge, MA, ⁶Sanofi, Unknown, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].